[开放获取]    中国麻风分子和免疫诊断专家共识（2024版）

doi:10.35541/cjd.20230376

Abstract

Abstract: 【Abstract】 Leprosy is a chronic infectious skin disease caused by Mycobacterium leprae. Traditionally, its diagnosis mainly relies on clinical manifestations and laboratory examinations which include slit-skin smears and histopathological examinations of skin biopsies. As to some suspected leprosy cases, such as paucibacillary leprosy or pure neural leprosy cases, it is difficult to diagnose using traditional laboratory tests, thus molecular and immunological examinations are necessary for auxiliary diagnosis. This expert consensus was developed based on Chinese and international literature and guidelines on leprosy diagnosis, aiming to promote early and precise diagnosis and treatment of leprosy.

Key words: Leprosy, Early diagnosis, Immunologic tests, Molecular diagnostic techniques, Drug resistance, bacterial

Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. -Expert consensus on the molecular and immunological diagnosis of leprosy in China （2024）[J]. Chinese Journal of Dermatology, 2024, 57(11): 969-975.doi:10.35541/cjd.20230376

References ［44］

［1］	Britton WJ, Lockwood DN. Leprosy［J］. Lancet, 2004,363（9416）:1209⁃1219. doi: 10.1016/S0140⁃6736（04）15952⁃7.
［2］	World Health Organization, Regional Office for South⁃East Asia. Guidelines for the diagnosis, treatment and prevention of leprosy［EB/OL］. （2018⁃10⁃06）［2023⁃06⁃28］. https://iris.who.int/handle/10665/274127.
［3］	World Health Organization. Global leprosy （Hansen disease） update, 2022: new paradigm⁃control to elimination［EB/OL］. （2023⁃09⁃14）［2024⁃09⁃15］. https://www.who.int/publications⁃detail⁃redirect/who⁃wer9837⁃409⁃430.
［4］	Srinivas G, Muthuvel T, Lal V, et al. Risk of disability among adult leprosy cases and determinants of delay in diagnosis in five states of India: a case⁃control study［J］. PLoS Negl Trop Dis, 2019,13（6）:e0007495. doi: 10.1371/journal.pntd.0007495.
［5］	中华人民共和国国家卫生健康委员会. WS 291⁃2018. 麻风病诊断［S/OL］.［2018⁃03⁃30］. https://www.nhc.gov.cn/wjw/s9491/201803/a8580254187c4f32bb8e5cc10cb9ea38.shtml.
［6］	Jiang H, Shi Y, Chokkakula S, et al. Utility of multi⁃target nested PCR and ELISPOT assays for the detection of paucibacillary leprosy: a possible conclusion of clinical laboratory misdiagnosis［J］. Front Cell Infect Microbiol, 2022,12:814413. doi: 10.3389/fcimb.2022.814413.
［7］	Martinez AN, Talhari C, Moraes MO, et al. PCR⁃based techniques for leprosy diagnosis: from the laboratory to the clinic［J］. PLoS Negl Trop Dis, 2014,8（4）:e2655. doi: 10.1371/journal.pntd.0002655.
［8］	Chauffour A, Morel F, Reibel F, et al. A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance［J］. Clin Microbiol Infect, 2021,27（11）:1601⁃1612. doi: 10.1016/j.cmi.2021.07.007.
［9］	Marques LÉC, Frota CC, Quetz JDS, et al. Evaluation of 16S rRNA qPCR for detection of Mycobacterium leprae DNA in nasal secretion and skin biopsy samples from multibacillary and paucibacillary leprosy cases［J］. Pathog Glob Health, 2018,112（2）:72⁃78. doi: 10.1080/20477724.2017.1415736.
［10］	Alifano P, Palumbo C, Pasanisi D, et al. Rifampicin⁃resistance, rpoB polymorphism and RNA polymerase genetic engineering［J］. J Biotechnol, 2015,202:60⁃77. doi: 10.1016/j.jbiotec.2014. 11.024.
［11］	Liesack W, Pitulle C, Sela S, et al. Nucleotide sequence of the 16S rRNA from Mycobacterium leprae［J］. Nucleic Acids Res, 1990,18（18）:5558. doi: 10.1093/nar/18.18.5558.
［12］	Li W, Matsuoka M, Kai M, et al. Real⁃time PCR and high⁃resolution melt analysis for rapid detection of Mycobacterium leprae drug resistance mutations and strain types［J］. J Clin Microbiol, 2012,50（3）:742⁃753. doi: 10.1128/JCM.05183⁃11.
［13］	Li X, Li G, Yang J, et al. Drug resistance （dapsone, rifampicin, ofloxacin） and resistance⁃related gene mutation features in leprosy patients: a systematic review and meta⁃analysis［J］. Int J Mol Sci, 2022,23（20）:12443. doi: 10.3390/ijms232012443.
［14］	Cambau E, Carthagena L, Chauffour A, et al. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy［J］. Clin Infect Dis, 2006,42（2）:238⁃241. doi: 10.1086/498506.
［15］	Comas I, Borrell S, Roetzer A, et al. Whole⁃genome sequencing of rifampicin⁃resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes［J］. Nat Genet, 2011,44（1）:106⁃110. doi: 10.1038/ng.1038.
［16］	Wu Z, Wang C, Wang Z, et al. Risk factors for dapsone resistance in leprosy patients: a systematic meta⁃analysis［J］. J Glob Antimicrob Resist, 2022,30:459⁃467. doi: 10.1016/j.jgar. 2022.05.015.
［17］	Wang C, Wu Z, Jiang H, et al. Global prevalence of resistance to rifampicin in Mycobacterium leprae: a meta⁃analysis［J］. J Glob Antimicrob Resist, 2022,31:119⁃127. doi: 10.1016/j.jgar.2022. 08.021.
［18］	Cambau E, Saunderson P, Matsuoka M, et al. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009⁃15［J］. Clin Microbiol Infect, 2018,24（12）:1305⁃1310. doi: 10.1016/j.cmi.2018.02.022.
［19］	Chokkakula S, Chen Z, Wang L, et al. Molecular surveillance of antimicrobial resistance and transmission pattern of Mycobacterium leprae in Chinese leprosy patients［J］. Emerg Microbes Infect, 2019,8（1）:1479⁃1489. doi: 10.1080/22221751. 2019.1677177.
［20］	Freitas AA, Oliveira RM, Hungria EM, et al. Alterations to antigen⁃specific immune responses before and after multidrug therapy of leprosy［J］. Diagn Microbiol Infect Dis, 2015,83（2）:154⁃161. doi: 10.1016/j.diagmicrobio.2015.06.021.
［21］	do Carmo Gonçalves A, Hungria EM, Freitas AA, et al. Leprosy surveillance study in a highly endemic Brazilian area using leprosy specific serologic tests and IFNγ whole blood assay［J］. Eur J Clin Microbiol Infect Dis, 2020,39（12）:2345⁃2360. doi: 10.1007/s10096⁃020⁃03979⁃5.
［22］	Hungria EM, Freitas AA, Pontes MA, et al. Antigen⁃specific secretion of IFNγ and CXCL10 in whole blood assay detects Mycobacterium leprae infection but does not discriminate asymptomatic infection from symptomatic leprosy［J］. Diagn Microbiol Infect Dis, 2017,87（4）:328⁃334. doi: 10.1016/j.diagmicrobio.2017.01.002.
［23］	Chen X, You YG, Yuan YH, et al. Evaluation of antigen⁃specific immune responses for leprosy diagnosis in a hyperendemic area in China［J］. PLoS Negl Trop Dis, 2018,12（9）:e0006777. doi: 10.1371/journal.pntd.0006777.
［24］	Chen X, You YG, Yuan YH, et al. Host immune responses induced by specific Mycobacterium leprae antigens in an overnight whole⁃blood assay correlate with the diagnosis of paucibacillary leprosy patients in China［J］. PLoS Negl Trop Dis, 2019,13（4）:e0007318. doi: 10.1371/journal.pntd.0007318.
［25］	Wang H, Liu W, Jin Y, et al. Detection of antibodies to both M. leprae PGL⁃I and MMP⁃II to recognize leprosy patients at an early stage of disease progression［J］. Diagn Microbiol Infect Dis, 2015,83（3）:274⁃277. doi: 10.1016/j.diagmicrobio.2015. 07.012.
［26］	Le W, Haiqin J, Danfeng H, et al. Monitoring and detection of leprosy patients in Southwest China: a retrospective study, 2010⁃2014［J］. Sci Rep, 2018,8（1）:11407. doi: 10.1038/s41598⁃018⁃29753⁃4.
［27］	Duthie MS, Raychaudhuri R, Tutterrow YL, et al. A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein⁃glycolipid conjugate［J］. Diagn Microbiol Infect Dis, 2014,79（2）:233⁃239. doi: 10.1016/j.diagmicrobio.2014.02.006.
［28］	Devides AC, Rosa PS, de Faria Fernandes Belone A, et al. Can anti⁃PGL⁃1 and anti⁃NDO⁃LID⁃1 antibody titers be used to predict the risk of reactions in leprosy patients?［J］. Diagn Microbiol Infect Dis, 2018,91（3）:260⁃265. doi: 10.1016/j.diagmicrobio.2018.03.002.
［29］	Canene⁃Adams K. General PCR［J］. Methods Enzymol, 2013,529:291⁃298. doi: 10.1016/B978⁃0⁃12⁃418687⁃3.00024⁃0.
［30］	Kamra E, Alam D, Singh V, et al. Diagnosis of urogenital tuberculosis by multiplex⁃nested PCR targeting mpt64 （Rv1980c） and IS6110: comparison with multiplex PCR and GeneXpert® MTB/RIF［J］. Lett Appl Microbiol, 2022,75（4）:857⁃868. doi: 10.1111/lam.13758.
［31］	Khosravi AD, Alami A, Meghdadi H, et al. Identification of Mycobacterium tuberculosis in clinical specimens of patients suspected of having extrapulmonary tuberculosis by application of nested PCR on five different genes［J］. Front Cell Infect Microbiol, 2017,7:3. doi: 10.3389/fcimb.2017.00003.
［32］	Chen X, He J, Liu J, et al. Nested PCR and the TaqMan SNP Genotyping Assay enhanced the sensitivity of drug resistance testing of Mycobacterium leprae using clinical specimens of leprosy patients［J］. PLoS Negl Trop Dis, 2019,13（12）:e0007946. doi: 10.1371/journal.pntd.0007946.
［33］	Wen Y, Xing Y, Yuan LC, et al. Whole⁃blood nested⁃PCR amplification of M. leprae⁃specific DNA for early diagnosis of leprosy［J］. Am J Trop Med Hyg, 2013,88（5）:918⁃922. doi: 10.4269/ajtmh.11⁃0253.
［34］	Banerjee S, Sarkar K, Gupta S, et al. Multiplex PCR technique could be an alternative approach for early detection of leprosy among close contacts⁃⁃a pilot study from India［J］. BMC Infect Dis, 2010,10:252. doi: 10.1186/1471⁃2334⁃10⁃252.
［35］	Martinez AN, Ribeiro⁃Alves M, Sarno EN, et al. Evaluation of qPCR⁃based assays for leprosy diagnosis directly in clinical specimens［J］. PLoS Negl Trop Dis, 2011,5（10）:e1354. doi: 10.1371/journal.pntd.0001354.
［36］	Kamal R, Dayal R, Katoch VM, et al. Analysis of gene probes and gene amplification techniques for diagnosis and monitoring of treatment in childhood leprosy［J］. Lepr Rev, 2006,77（2）:141⁃146.
［37］	Dayal R, Agarwal PK, Kalra K, et al. Diagnostic value of gene probes and its correlation with clinical profile of leprosy in children［J］. Indian Pediatr, 1994,31（12）:1521⁃1527.
［38］	Chen X, You YG, Yuan YH, et al. Evaluation of antigen⁃specific immune responses for leprosy diagnosis in a hyperendemic area in China［J］. PLoS Negl Trop Dis, 2018,12（9）:e0006777. doi: 10.1371/journal.pntd.0006777.
［39］	Wen Y, You YG, Yuan LC, et al. Evaluation of novel tools to facilitate the detection and characterization of leprosy patients in China［J］. Biomed Res Int, 2014,2014:371828. doi: 10.1155/2014/371828.
［40］	张秀明, 熊继红, 杨有业. 临床检验质量管理与标准操作程序［M］. 北京: 人民医学出版社, 2011.
［41］	中华人民共和国国家卫生健康委员会. GB/T 20468⁃2006. 临床实验室定量测定室内质量控制指南［S/OL］. （2006⁃09⁃01）［2024⁃10⁃21］. http://www.nhc.gov.cn/wjw/s9492/201409/8da8601c27e941b5a650cdfc0da97e2f.shtml.
［42］	王治国. 临床检验质量控制技术［M］. 北京: 人民卫生出版社, 2008.
［43］	中华人民共和国国家卫生和计划生育委员会. WS 288⁃2017肺结核诊断［J］. 结核与肺部疾病杂志, 2024,5（4）:376⁃378. doi: 10.19983/j.issn.2096⁃8493.2024022.
［44］	国家疾病预防控制局. 关于印发《全面消除麻风危害可持续发展规划（2024—2030年）》的通知［EB/OL］. ［2024⁃01⁃28］. https://www.ndcpa.gov.cn/jbkzzx/c100014/common/content/content_ 1750803396654190592.html.

[1]	Wu Chengyu, Wang Peng, Kang Xiaojing. Identification and typing of Kaposi′s sarcoma-associated herpesvirus [J]. Chinese Journal of Dermatology, 2024, 57(3): 275-278.
[2]	Sun Peiwen, Wang Le, Wang Hongsheng, Yan Liangbin, Yu Meiwen. Epidemiological characteristics of leprosy in China from 2016 to 2020 [J]. Chinese Journal of Dermatology, 2023, 56(3): 204-209.
[3]	Yang Ji, Xu Xinzhi, Li Ming. Early diagnosis of dermatomyositis and early recognition of visceral injury [J]. Chinese Journal of Dermatology, 2023, 56(2): 161-164.
[4]	Xia Ruiyuan, Long Fangyuan, Yin Zhiqiang. Relationship between psoriatic arthritis and nail psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(11): 1061-1064.
[5]	Chen Huan, Yin Jiangliu. Screening of differentially expressed genes in CD4⁺ T cells in peripheral blood of 45 leprosy patients [J]. Chinese Journal of Dermatology, 2021, 54(8): 683-687.
[6]	Yan Yunling, Zheng Baoqing, He Xueyu, Cheng Qing, Wang Xiaohua. Expression of solute carrier proteins SLC35E1 and SLC35E2B in skin lesions of patients with Mycobacterium infections [J]. Chinese Journal of Dermatology, 2021, 54(4): 347-351.
[7]	. Preliminary analysis of the value of Fite staining in the diagnosis of leprosy [J]. Chinese Journal of Dermatology, 2018, 51(9): 662-664.
[8]	. Efficacy comparison of uniform versus routine multidrug therapy for the treatment of multi-bacillary leprosy patients based on bacterial index and leprosy reactions [J]. Chinese Journal of Dermatology, 2012, 45(8): 553-556.
[9]	. Expressions of Toll-like receptor 2 and 4 in peripheral blood monouclear cells of patients with leprosy [J]. Chinese Journal of Dermatology, 2010, 43(9): 623-625.
[10]	WU Qin-xue, ZHANG Liang-fen, CHEN Xiao-hong, YIN Yue-ping, YU Yan-hua, LI Zhi-cheng, YU Hua, SHI Yue-jun, LU Cheng-zhi, LIN Jun-lun, FENG Su-ying, LI Xiao-jie. Detecting Serum IgM-antibody in Cured Leprosy Patients by ND-ELISA: A Result of Three-Year Followe up [J]. Chinese Journal of Dermatology, 2004, 37(9): 537-539.
[11]	Zhang Guocheng, Yan Liangbin, Jiang Juan. Results of Field Trial of POD and Rehabilitation in Leprosy [J]. Chinese Journal of Dermatology, 1998, 31(6): 351-353.
[12]	Shen Jianping, Li Wenzhong, Wei Wanhui. Monitoring High Risk Group of Leprosy by Lepromin Test and Serologic Test [J]. Chinese Journal of Dermatology, 1997, 30(6): 392-394.
[13]	Gao Jincheng, Zheng Bizhong, Fang Hailin. Study of Tumor Necrosis Factor α in Cured Leprosy Patients [J]. Chinese Journal of Dermatology, 1997, 30(5): 321-323.
[14]	Yan Liangbin, Zhang Guocheng, Li Wenzhong. An Epidemiological Survey of Eye Complications in Leprosy Patients [J]. Chinese Journal of Dermatology, 1996, 29(4): 252-254.
[15]	Shen Jianping, Li Wenzhong, Yan Liangbin. Results of Multidrug Therapy on Multibacilary Leprosy and Folow up of Ten Years [J]. Chinese Journal of Dermatology, 1996, 29(4): 255-257.

-Expert consensus on the molecular and immunological diagnosis of leprosy in China （2024）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［44］

Related Articles 15

Metrics

Comments

Recommended 10